Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 5/20 | 0.48 |
| ▸ | CHUK | O15111 | 14/20 | 0.46 |
| ▸ | IKBKB | O14920 | 11/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | INSR | P06213 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838420 | 0.85 | BRD4 (0.43) | NEK1CHUKIKBKBINSRMAPK8 | |
| SCHEMBL1837314 | 0.82 | CHUK (0.62) | CHUKIKBKBINSRMAPK8CAMKK2 | |
| SCHEMBL2240207 | 0.78 | NEK1 (0.41) | NEK1CHUKIKBKBROCK1MAPK8 | |
| SCHEMBL12354047 | 0.75 | PIK3CD (0.43) | CHUKIKBKBROCK1INSRMAPK8 | |
| SCHEMBL1836679 | 0.73 | PIK3CD (0.46) | CHUKINSRMAPK8CAMKK2 | |
| SCHEMBL3417349 | 0.69 | IKBKB (0.89) | NEK1CHUKIKBKBCYP2C9ROCK1 | |
| SCHEMBL1839203 | 0.68 | CHUK (0.67) | CHUKIKBKBINSRMAPK8CAMKK2 | |
| SCHEMBL2322063 | 0.67 | BRD4 (0.47) | CHUKIKBKBCYP2C9BRAFBRD4 | |
| SCHEMBL3416043 | 0.66 | IKBKB (0.68) | NEK1CHUKIKBKBCYP2C9ROCK1 | |
| SCHEMBL1840342 | 0.64 | IGF1R (0.60) | CHUKIKBKBROCK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011526931-A | — | — | 2011-10-20 | — | — | JP | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | claimed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | claimed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | NEK1 349/4885CHUK 163/4885IKBKB 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.